Updates are available Correction dated 2021-03-05
Click to view Correction: https://doi.org/10.1038/s41597-021-00865-3
-
Authors
Rotemberg, Veronica https://orcid.org/0000-0003-0639-2677
Kurtansky, Nicholas
Betz-Stablein, Brigid https://orcid.org/0000-0003-3876-501X
Caffery, Liam
Chousakos, Emmanouil https://orcid.org/0000-0002-8127-4761
Codella, Noel
Combalia, Marc
Dusza, Stephen
Guitera, Pascale
Gutman, David
Halpern, Allan
Helba, Brian
Kittler, Harald https://orcid.org/0000-0002-0051-8016
Kose, Kivanc https://orcid.org/0000-0003-3185-2639
Langer, Steve
Lioprys, Konstantinos
Malvehy, Josep
Musthaq, Shenara
Nanda, Jabpani
Reiter, Ofer
Shih, George
Stratigos, Alexander
Tschandl, Philipp https://orcid.org/0000-0003-0391-7810
Weber, Jochen
Soyer, H. Peter https://orcid.org/0000-0002-4770-561X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (NIH/NCI Cancer Center Support Grant P30 CA008748)
Melanoma Research Alliance (Young Investigator Award 614197)
Australian Cancer Research Foundation (Australian Centre of Excellence in Melanoma Imaging & Diagnosis (ACEMID))
Department of Health | National Health and Medical Research Council (APP1099021)
- License Information
-
More Information
Article History
Received: 26 August 2020
Accepted: 18 December 2020
First Online: 28 January 2021
Change Date: 5 March 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41597-021-00865-3
Competing interests
: H.P.S. is a shareholder of MoleMap N.Z. Limited and e-derm consult GmbH, and undertakes regular teledermatological reporting for both companies. H.P.S. is a Medical Consultant for Canfield Scientific Inc., Revenio Research Oy and also a Medical Advisor for First Derm. AH serves as a consultant to Canfield Scientific Inc., and is on the SciBase advisory panel.
